CRISPR off target turn
Marsha Greene & Zubin Master, 2018, Senior Policy Analyst, Peraton & Biomedical Ethics Research Program, Mayo Clinic, https://www.ndu.edu/Portals/59/Documents/Incoming/AY21%20Briefings/NDU%206070/CRISPR_Military.pdf?ver=2020-08-11-170728-347, " Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement" Journal of Bioethical Inquiry (ermo/sms, Acc:6-8-2022)
Considering that military service members already take significant risks simply by enlisting in the armed services, the risk/benefit analysis for research may be more favourable towards gene enhancement as the enhancement itself could improve the chances of survival during armed conflict (Annas and Annas 2009). Nevertheless, the risks of research must be addressed in a systematic manner to ensure that service members are not being exposed to unnecessary harm. Most concerning with gene editing research using CRISPR is the potential for off-target effects. If the CRISPR machinery accidentally docks at an unintended location in the genome it could cause mutations and disrupt or accelerate nontargeted biological processes thereby resulting in any number of illnesses, some of which may be life threatening. Nevertheless, the possibility of significant off target effects remains hypothetical. A recent report indicating that CRISPR gene editing had caused over one thousand single nucleotide mutations and over one hundred deletions was later retracted after heavy criticism of the scientific methods used and the validity of the paper’s conclusions (Schaefer et al. 2017; Wilson et al. 2017; Nature Methods, 2018). Nevertheless, our knowledge of biological processes and potential CRISPR effects remains limited. The risk–benefit calculus would require military IRBs to balance risks of off-target effects against the potential benefits of improved survival. The risks would be difficult to predict because more research on the frequency of off-target effects needs to be done in order to determine whether the benefits outweigh the risks. Risks may be minimized through preclinical experiments using robust animal models, reliable measures of off-target effects, and from an adequate understanding of how gene changes affect biological function. Risks may also be minimized if a reversible system was used.